



MetrioPharm AG: Conversion of bearer shares to registered shares

Zurich, 27th of November 2009: According to the resolution of an extraordinary general meeting of MetrioPharm AG (WKN: A0MLMB; ISIN: CH0029188817) on 30th of September 2009 share certificates of the company will be converted from bearer shares to registered shares. The depositary banks were requested to transfer the stock portfolio of their bailers from bearer shares to registered shares at a ratio of 1:1 and to fulfill the registration in the share register.

The bearer shares of MetrioPharm AG will be traded until the 30th of November 2009 at the Frankfurt Stock Exchange. The trading of the registered shares with a new ISIN code CH0107076744 will start on 1st of December 2009.

„Due to the conversion to registered shares and shareholder entry in the share register of the company we will be able to improve our investor relations substantially. Since we are now able to build up a direct contact to institutional as well as private investors we can achieve a sustainable and long-term cost advantage through the maintenance of the share register. Company information such as general meeting invitations, corporate news or annual reports can reach the recipients without any spreading losses”, explained Dr. Wolfgang Brysch, president of the advisory board of MetrioPharm AG.

The company will henceforth recognize only those persons who are registered in the share register as shareholders. The previous owners of bearer shares are requested either to be confirmed by their depositary bank that their registration occurred or to get in touch with the company themselves. The conversion of bearer shares to registered shares will not affect the legal status of the share holders. The conversion of the bearer shares to registered shares is exempt from charges for the shareholders. The new registered shares are entitled to dividend for the whole business year 2009.

About MetrioPharm AG:

MetrioPharm AG is a biotechnology company which focuses on the development and registration of small-molecular drugs in advanced developmental stages, for which there is already clinical evidence for efficacy in humans.

Company Contact:

MetrioPharm AG
Neuendorfstraße 20B
16761 Hennigsdorf
www.metriopharm.com
T. +49 (0) 3302 20 234 02
F. +49 (0) 3302 20 234 99
info@metriopharm.com

Investor Relations Contact:

GFEI Aktiengesellschaft
Hamburger Allee 26-28
60486 Frankfurt am Main
www.gfei.de
T. +49 (0) 69 743 037 00
F. +49 (0) 69 743 037 22
metriopharm@gfei.de